Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Current Assets (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Current Assets for 5 consecutive years, with $125.7 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Current Assets fell 19.86% year-over-year to $125.7 million, compared with a TTM value of $125.7 million through Dec 2024, down 19.86%, and an annual FY2024 reading of $125.7 million, down 19.86% over the prior year.
  • Current Assets was $125.7 million for Q4 2024 at Barinthus Biotherapeutics, down from $131.9 million in the prior quarter.
  • Across five years, Current Assets topped out at $256.7 million in Q2 2021 and bottomed at $47.9 million in Q4 2020.
  • Average Current Assets over 5 years is $184.0 million, with a median of $192.7 million recorded in 2023.
  • The sharpest move saw Current Assets skyrocketed 373.4% in 2021, then fell 28.67% in 2024.
  • Year by year, Current Assets stood at $47.9 million in 2020, then surged by 373.4% to $226.8 million in 2021, then fell by 6.05% to $213.0 million in 2022, then dropped by 26.35% to $156.9 million in 2023, then decreased by 19.86% to $125.7 million in 2024.
  • Business Quant data shows Current Assets for BRNS at $125.7 million in Q4 2024, $131.9 million in Q2 2024, and $143.1 million in Q1 2024.